The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

746

Participants

Timeline

Start Date

February 1, 2014

Primary Completion Date

June 26, 2016

Study Completion Date

July 31, 2017

Conditions
Delirium
Interventions
DRUG

Ketamine (0.5 mg/kg)

Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.

DRUG

Normal Saline (placebo)

Normal saline IV following induction of anesthesia or administration of sedative medications

DRUG

Ketamine (1 mg/kg)

Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Harvard Medical School (HMS and HSDM)

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

collaborator

University of Bern

OTHER

collaborator

University of Michigan

OTHER

collaborator

University of Manitoba

OTHER

collaborator

University Health Network, Toronto

OTHER

collaborator

Virginia Mason Hospital/Medical Center

OTHER

lead

Washington University School of Medicine

OTHER

NCT01690988 - The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial | Biotech Hunter | Biotech Hunter